Mucosta Adverse Reactions

The following summary of data includes adverse reactions voluntarily reported after marketing (Figures are total cases reported at the time of approval and at the completion of reexamination of MUCOSTA Tablets) in Japan.
Clinically significant adverse reactions: Shock, anaphylactoid reactions (incidence unknown*): Shock or anaphylactoid reactions may occur. Patients should therefore be closely monitored. If abnormal findings are observed, the drug should be discontinued, and appropriate measures taken.
Leukopenia (incidence <0.1%) and thrombocytopenia (incidence unknown*): Leukopenia and thrombocytopenia may occur. Patient should therefore be closely monitored. If abnormal findings are observed, the drug should be discontinued and appropriate measures taken.
Hepatic dysfunction (incidence <0.1%) and jaundice (incidence unknown*): Hepatic dysfunction and jaundice, as indicated by increases in AST (GOT), ALT (GPT), y-GTP, and alkaline phosphatase levels, have been reported in patients receiving MUCOSTA Tablets. Patient should therefore be closely monitored. If abnormal laboratory findings are observed, the drug should be discontinued, and appropriate measures taken.
Other adverse reactions: (See table.)

Click on icon to see table/diagram/image